KalVista Pharmaceuticals (KALV) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for KalVista Pharmaceuticals (KALV) over the last 1 years, with Apr 2025 value amounting to -$0.91.
- KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) rose 14.95% to -$0.91 in Q2 2025 from the same period last year, while for Apr 2025 it was -$3.69, marking a year-over-year decrease of 43.46%. This contributed to the annual value of -$3.69 for FY2025, which is 7.27% down from last year.
- Per KalVista Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.91 for Q2 2025, which was down 4.60% from -$0.87 recorded in Q3 2024.
- In the past 5 years, KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of -$0.84 in Q1 2024 and a low of -$1.07 during Q2 2024.
- For the 2-year period, KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around -$0.92, with its median value being -$0.89 (2025).
- Data for KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) shows a peak YoY increased of 14.95% (in 2025) over the last 5 years.
- KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.87 in 2024, then increased by 14.95% to -$0.91 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.91 for Q2 2025, versus -$0.87 for Q3 2024 and -$1.07 for Q2 2024.